Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Dasatinib (Primary)
- Indications Advanced breast cancer
- Focus Biomarker; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 18 Apr 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jan 2019.
- 27 Sep 2016 Status changed from active, no longer recruiting to recruiting.